Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

Decitabine,2353-33-5
Decitabine
Decitabine,2353-33-5
Product Name
Decitabine
Synonyms
5-Aza-2'-deoxycytidine
Systematic Name
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-
CAS No.
2353-33-5
Molecular Formula 
C8H12N4O4   
Molecular Weight
228.2068
Certificate of analysis
Decitabine,2353-33-5
View via PDF file
Decitabine,2353-33-5
Specification
Items
Specification
Test result
Appearance
White crystalline powder, odorless
Complies
Solubility
Slightly soluble in methanol
Complies
Identification
IR,UV,HPLC
Complies
Specific Rotation
+ 65°~ + 73° in methanol 10 mg/ML
Complies
Melting point
192 ℃ ~ 195 ℃
Complies
Related substances
Alpha isomer: ≤0.5%
Each unknown individual: ≤0.5%
Total impurity: ≤1.0%
0.22%
0.13%
0.5%
Loss on drying
≤1.0%
0.006%
Purity(HPLC)
≥99.0%
99.6%
Heavy metals
≤10ppm
Complies
Residues after ignition
≤0.1%
0.02%
Residual Solvents
Methanol: ≤2000ppm
Ethyl acetate: ≤2000ppm
Toluene ≤800ppm
Ethanol : ≤2000ppm
Complies
Assay
98.0~102.0% on anhydrous and solvent free
basis
99.6%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Decitabine,2353-33-5
Packing 1
100mg
Packing 2
1g
Packing 3
5g
   
   
Bulk request
sales@lanospharma.com
Related Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Decitabine,5-Aza-2'-deoxycytidine,2353-33-5).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.